Exagen Inc. (XGN)
NASDAQ: XGNHealth CareMedical SpecialitiesUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
XGN stock chart
Technical analysisKey statistics
All statistics- Market cap
- $92.10M
- EPS (TTM)
- -$0.76
- Dividend yield
- None
- 52-week range
- 2.59 – 9.22
- Day range
- 3.48 – 3.90
- Volume / Avg
- 508.83K / 470.43K
- Beta
- —
- Shares outstanding
- 25.51M
52-week range
XGN stock today
On Nov 20, XGN ended the session at $3.61, shedding $0.19 (5.00%), versus the S&P 500's 3.70% decline. Shares are 60.8% below their 52-week high of $9.22, set on Oct 14, 2026 and 39.4% above the 52-week low of $2.59, near the bottom of the past year's range. XGN is down 40.6% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 52.6%.
Exagen has posted a net loss over the last twelve months (EPS of -$0.76), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Exagen
Company profileExagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).
- Sector
- Health Care
- Industry
- Medical Specialities
- CEO
- Mr. John Aballi
- Headquarters
- Vista, CA
- Employees
- 216
- IPO year
- 2019
- Website
- exagen.com
Financial highlights
Full financialsIn fiscal 2025, Exagen generated $66.6 million in revenue, up 19.7% from fiscal 2024, its 3rd consecutive year of revenue growth. Exagen reported a net loss of $20.0 million, compared with a loss of $15.1 million a year earlier. Gross margin was 58.3% (down from 59.5%) and operating margin -21.1%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $66.58M | $55.64M | $52.55M | $45.56M | $48.30M |
| Growth | +19.65% | +5.89% | +15.33% | -5.66% | +15.07% |
| Net income | $-19.95M | $-15.12M | $-23.69M | $-47.39M | $-26.85M |
| EPS (diluted) | $-0.93 | $-0.83 | $-1.34 | $-2.77 | $-1.68 |
Analyst forecast
ForecastConsensus (7 analysts)
strong_buy
Avg. price target
$10.29+185.04%
- Strong buy 0
- Buy 7
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 10, 2026
- EPS actual vs est.
- $-0.19 vs $-0.19
- Surprise
- 0.00%
XGN news
All XGN news- Exagen (XGN) Q3 2026 Earnings Call TranscriptNasdaq
- Exagen Inc. Reports Third Quarter 2026 Financial ResultsGlobeNewswire
- Exagen is Now Oversold (XGN)Nasdaq
- Zimmer Biomet (ZBH) Q3 Earnings and Revenues Beat EstimatesNasdaqZBH, XGN
- Exagen Inc. to Participate in Upcoming Investor ConferencesGlobeNewswire
- Exagen to Announce Third Quarter Financial Results on November 10, 2026GlobeNewswire
Exagen peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| KEQUKewaunee Scientific Corporation | 33.55 | -2.75% | $97.14M | vs XGN |
| BDSXBiodesix Inc. | 7.56 | -8.92% | $83.83M | vs XGN |
| SERASera Prognostics Inc. Class A | 1.81 | -4.23% | $71.98M | vs XGN |
| BNRBurning Rock Biotech Limited ADR | 13.24 | -0.60% | $139.63M | vs XGN |
| TLSITriSalus Life Sciences Inc. | 2.32 | +6.67% | $143.14M | vs XGN |
| MDXHMDxHealth SA | 0.1074 | -8.52% | $10.25M | vs XGN |
| AMSAmerican Shared Hospital Services | 1.00 | -4.76% | $6.67M | vs XGN |
| ACONAclarion Inc. | 1.22 | -13.92% | $3.52M | vs XGN |
Indexes, lists and sector
Exagen stock FAQ
What is Exagen's stock price today?
XGN last traded at $3.61 as of Nov 20, 4:00 PM EST, down 5.00% on the day. Prices are delayed at least 15 minutes.
Who is Exagen's CEO?
Mr. John Aballi is the chief executive officer of Exagen Inc., which has about 216 employees.
What is the XGN 52-week high?
The 52-week high for XGN is $9.22 and the 52-week low is $2.59. The stock is currently 60.8% below its high.